posaconazole

Over the last decade, the introduction of new antifungal drugs and diagnostic procedures has improved the prognosis of hematological patients with invasive fungal disease (IFD), primarily invasive aspergillosis. Despite effective antifungal …

Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole. Clinical studies have demonstrated …

Objective. To assess the incidence rate, risk factors and treatment outcomes of mucormycosis in children with hematological malignancies in the large tertiary hematology/oncology center. Materials and Methods. A total of 16 children (9 males/7 females) with mucormycosis were enrolled in a single-center, retrospective study over the period of 2012–2018. All patients had an underlying diagnosis of acute leukemia. Mucormycosis was diagnosed at the different timepoints after chemotherapy (CT) or hematopoietic stem cell transplantation (HSCT) in 15 cases and before CT in 1 case.

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the …

For the first time in Russian economic conditions and with use of mathematic modeling, clinical-economic study of posaconazole in comparison with fluconazole/itraconazole for primary prophylaxis of invasive mycoses in patients with severe neutropenia …